scispace - formally typeset
A

Abdul Jabbar

Researcher at Eli Lilly and Company

Publications -  7
Citations -  243

Abdul Jabbar is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Type 2 Diabetes Mellitus & Insulin. The author has an hindex of 5, co-authored 7 publications receiving 178 citations.

Papers
More filters
Journal ArticleDOI

Multi-country retrospective observational study of the management and outcomes of patients with Type 2 diabetes during Ramadan in 2010 (CREED).

TL;DR: To describe the characteristics and management of patients with diabetes who chose to fast during Ramadan in 2010, a large number of them chose tofast during Ramadan.
Journal ArticleDOI

CREED study: Hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continents

TL;DR: Approaches to the management of Type 2 diabetes mellitus during Ramadan varied across regions, and Episodes of hypoglycaemia and insulin therapy predicted risk of hyp glucosecaemia during Ramadan and identified individuals who required Ramadan-specific education.
Journal ArticleDOI

Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review.

TL;DR: The primary aim of this systematic review was to provide an overview of the efficacy and safety of premixed insulin analogs in Asians, specifically East Asians, with type 2 diabetes.
Journal Article

Titration of Insulin Glargine in Patients with Type 2 Diabetes Mellitus in Asia: Physician- Versus Patient-Led? Rationale of the Asian Treat to Target Lantus Study (ATLAS)

TL;DR: ATLAS will provide information on the relative safety and efficacy of a patient- versus physician-led titration strategy for insulin glargine-based basal insulin initiation in patients who are not controlled with two OADs in Asia and Russia.
Journal ArticleDOI

Patterns and trends in insulin initiation and intensification among patients with type 2 diabetes mellitus in the Western Pacific region.

TL;DR: Data from PROs suggests that the insulin treatment improves QoL in most patients, as high HbA1C levels indicate a delayed start of insulin Therapy, timely initiation and early intensification of insulin therapy is necessary in the region to achieve adequate glycemic control in time and prevent diabetes complications.